Bayer’s Xarelto shows benefits for treatment of atrial fibrillation

Bayer has reported new clinical data showing the effectiveness of Xarelto in the treatment of patients with non-valvular atrial fibrillation.

Data from the phase IIIb Pioneer AF-PCI study demonstrated that two different treatment strategies with Xarelto both significantly reduced the risk of bleeding, compared to a vitamin K antagonist (VKA) treatment strategy, in patients with non-valvular AF after a percutaneous coronary intervention (PCI) with stent placement.

A once-daily 15 mg dose of Xarelto in combination with single antiplatelet therapy was shown to significantly reduce the rate of clinically significant bleeding by 41 percent compared to VKA plus dual antiplatelet therapy over 12 months of randomised therapy.

Meanwhile, a 2.5 mg twice daily dose in combination with dual antiplatelet therapy reduced the rate of bleeding by 37 per cent, which was also deemed to be a statistically significant benefit.

Dr Michael Devoy, head of medical affairs and pharmacovigilance of Bayer's pharmaceuticals division and the company's chief medical officer, said: "Pioneer AF-PCI answers an important medical question, because it is potentially relevant for the 20 to 45 percent of AF patients that also have coronary artery disease and are at risk of having to have a PCI."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.